相似文献
1
Reconsidering the Usefulness of Adding Naloxone to Buprenorphine.
Front Psychiatry. 2020 Sep 11;11:549272. doi: 10.3389/fpsyt.2020.549272. eCollection 2020.
2
Buprenorphine-containing treatments: place in the management of opioid addiction.
CNS Drugs. 2006;20(9):697-712. doi: 10.2165/00023210-200620090-00001.
3
Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.
4
Opioid dependence treatment, including buprenorphine/naloxone.
Ann Pharmacother. 2002 Feb;36(2):312-21. doi: 10.1345/aph.10421.
5
Buprenorphine treatment for narcotic addiction: not without risks.
Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):32-6.
6
Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
Adv Ther. 2018 Apr;35(4):457-466. doi: 10.1007/s12325-018-0696-y. Epub 2018 Apr 6.
7
Justice involvement patterns, overdose experiences, and naloxone knowledge among men and women in criminal justice diversion addiction treatment.
Harm Reduct J. 2019 Jul 16;16(1):46. doi: 10.1186/s12954-019-0317-3.
8
Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
Clin Drug Investig. 2010;30 Suppl 1:13-9. doi: 10.2165/11536040-000000000-00000.
9
Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
Psychopharmacology (Berl). 2000 Mar;148(4):374-83. doi: 10.1007/s002130050066.
10
Buprenorphine for the treatment of opioid dependence.
Am J Health Syst Pharm. 2007 Feb 1;64(3):266-72. doi: 10.2146/ajhp060403.
引用本文的文献
1
Medications for opioid use disorder shape immune responses during chronic HIV infection.
Cell Rep Med. 2025 Jun 17;6(6):102159. doi: 10.1016/j.xcrm.2025.102159. Epub 2025 Jun 2.
2
Community pharmacy attitudes and behaviors following a buprenorphine best practices dissemination.
Ment Health Clin. 2025 Apr 4;15(2):43-50. doi: 10.9740/mhc.2025.04.043. eCollection 2025 Apr 1.
3
Buprenorphine/naloxone - one formulation that doesn't fit all: a case report.
Harm Reduct J. 2024 Jul 30;21(1):143. doi: 10.1186/s12954-024-01054-2.
4
Endogenous and Exogenous Opioids: Role in Substance Use Disorders.
Adv Neurobiol. 2024;35:267-285. doi: 10.1007/978-3-031-45493-6_14.
5
Buprenorphine, Norbuprenorphine, and Naloxone Levels in Adulterated Urine Samples: Can They be Detected When Buprenorphine/Naloxone Film is Dipped into Urine or Water?
Subst Use. 2024 Jan 20;18:11782218231223673. doi: 10.1177/11782218231223673. eCollection 2024 Jan-Dec.
6
An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine.
Pharmaceuticals (Basel). 2023 Oct 2;16(10):1397. doi: 10.3390/ph16101397.
7
Large variations in all-cause and overdose mortality among >13,000 patients in and out of opioid maintenance treatment in different settings: a comparative registry linkage study.
Front Public Health. 2023 Sep 22;11:1179763. doi: 10.3389/fpubh.2023.1179763. eCollection 2023.
8
Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements.
JAMA Netw Open. 2023 Jun 1;6(6):e2318487. doi: 10.1001/jamanetworkopen.2023.18487.
9
Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
J Subst Use Addict Treat. 2023 Jun;149:209028. doi: 10.1016/j.josat.2023.209028. Epub 2023 Mar 31.
10
Suboxone: History, controversy, and open questions.
Front Psychiatry. 2022 Oct 28;13:1046648. doi: 10.3389/fpsyt.2022.1046648. eCollection 2022.
本文引用的文献
1
Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence.
Drug Saf. 2018 Oct;41(10):981-988. doi: 10.1007/s40264-018-0653-3.
2
Buprenorphine alone or with naloxone: Which is safer?
J Psychopharmacol. 2018 Mar;32(3):344-352. doi: 10.1177/0269881118756015. Epub 2018 Feb 13.
3
Time-dependent neuronal changes associated with craving in opioid dependence: an fMRI study.
Addict Biol. 2018 Sep;23(5):1168-1178. doi: 10.1111/adb.12554. Epub 2017 Sep 22.
4
Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.
Drug Alcohol Depend. 2017 Oct 1;179:362-369. doi: 10.1016/j.drugalcdep.2017.06.033. Epub 2017 Jul 26.
5
Motivational Processes Underlying Substance Abuse Disorder.
Curr Top Behav Neurosci. 2016;27:473-506. doi: 10.1007/7854_2015_391.
6
How fast and how often: The pharmacokinetics of drug use are decisive in addiction.
Neurosci Biobehav Rev. 2015 Sep;56:166-79. doi: 10.1016/j.neubiorev.2015.06.012. Epub 2015 Jun 24.
7
A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.
J Addict Med. 2014 Sep-Oct;8(5):315-26. doi: 10.1097/ADM.0000000000000045.
8
Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.
Addict Biol. 2015 Jul;20(4):784-98. doi: 10.1111/adb.12163. Epub 2014 Jul 25.
9
Urine naloxone concentration at different phases of buprenorphine maintenance treatment.
Drug Test Anal. 2014 Mar;6(3):220-5. doi: 10.1002/dta.1464. Epub 2013 Mar 19.
10
Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
Drug Alcohol Depend. 2011 Nov 1;118(2-3):265-73. doi: 10.1016/j.drugalcdep.2011.04.002. Epub 2011 May 12.
Zotero 插件